Showing results (11-20 of 73) with videos related to
Sort By:
Pageof 8
Cancer|May 4, 2011
Prevalence of complementary medicine use in a phase 1 clinical trials program: the MD Anderson Cancer Center ExperienceAung Naing, Saneese K Stephen, Moshe Frenkel, et al.Investigational New Drugs|April 18, 2019
A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumorsJeffrey P Sharman, Jennifer J Wheler, Lawrence Einhorn, et al.Oncoscience|August 5, 2016
Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitorsJennifer J Wheler, Johnique T Atkins, Filip Janku, et al.Cancer Chemotherapy and Pharmacology|April 18, 2016
Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancerRabih Said, Eugenia Kakadiaris, Sarina Piha-Paul, et al.Oncotarget|April 19, 2014
Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimusSarina A Piha-Paul, Jennifer J Wheler, Siqing Fu, et al.Investigational New Drugs|August 3, 2013
Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignanciesGerald S Falchook, Siqing Fu, Aung Naing, et al.Molecular Cancer Therapeutics|August 22, 2013
Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutationsJennifer J Wheler, Apostolia M Tsimberidou, Gerald S Falchook, et al.Journal of Cancer Research and Clinical Oncology|March 5, 2013
Factors related to biopsy willingness in patients with advanced cancer in a phase 1 clinic for molecularly targeted therapyDavid S Hong, Goldy C George, Eucharia C Iwuanyanwu, et al.Investigational New Drugs|March 31, 2015
Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancerDavid S Hong, Filip Janku, Aung Naing, et al.Cancer Chemotherapy and Pharmacology|February 11, 2015
Phase I trial of valproic acid and lenalidomide in patients with advanced cancerMehmet Asim Bilen, Siqing Fu, Gerald S Falchook, et al.Pageof 8